Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec;96(50):e9276.
doi: 10.1097/MD.0000000000009276.

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report

Affiliations
Case Reports

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report

Chunbo Zhao et al. Medicine (Baltimore). 2017 Dec.

Abstract

Rationale: The outcomes of locally advanced non-small cell lung cancer (NSCLC) remain poor, in particular, the frail elderly patients cannot tolerate chemotherapy. The new efficient, safe, and more specific treatments are needed. Radiation combined with targeted therapy is the focus of research in recent years. Apatinib is highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, studies have revealed that apatinib inhibit the growth of solid tumors including NSCLC. However, there is no report to evaluate its efficacy and safety in combined with radiotherapy for the advanced NSCLC. Our original research about to explore the use of apatinib combined with radiotherapy in treatment of NSCLC and its side effects are as follows.

Patient concerns: Patient 1, man, 78-year old, admitted to hospital, due to "thoracalgia and dyspnea for 1 month." Chest and abdomen computed tomography (CT) scan showed that there was a huge mass at the left upper lobe and multiple lymph nodes metastasis in mediastinum and left hilus pulmonis, the diagnosis was left lung squamous cell carcinoma, however, the mass was huge and age of patient was elder, post chemotherapy the mass were bigger and more severe. Patient 2, man, 61-year old, the diagnosis was squamous carcinoma on left upper lobe with right mediastinum lymph notes metastases recrudescence post chemoradiotherapy.

Diagnoses: Case 1 was diagnosed left lung huge squamous cell carcinoma and case 2 was left lung squamous carcinoma, the primary lesion and right mediastinum lymph notes metastases recrudescence after radiochemotherapy.

Interventions: Both patients who received local radiation therapy and concurrent apatinib. Apatinib 250 mg once daily in combination with thoracic radiotherapy (2 Gy/d, 5 fractions/wk) followed by Apatinib Maintenance Therapy.

Outcomes: Favorable oncologic outcomes were achieved in the 2 cases after the treatment. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of was controllable and tolerable, no dyspnea, no hemoptysis, no thoracalgia.

Lessons: Apatinib combined with thoracic radiotherapy, may be an option for recurring or advanced NSCLC. But that still warrants further investigation in the prospective study.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
A and B: CT scan showed that there was a huge mass at the left upper lobe multiple lymph nodes metastasis in mediastinum and left hilus pulmonis. C: The target range of irradiation including the left lung primary tumor and mediastinal lymph node metastasis (V-MAT 2 Gy/F total DT: 60 Gy/30F). D and E: 1 month after treatment (January, 2017) CT scan showed that therapeutic evaluation was partial remission (PR) and the mass reduced partially. F and G: Three months after treatment (April, 2017) CT scan showed that the interior of the tumor was necrosis, cavity formation, wall nodules formation. CT = computed tomography.
Figure 2
Figure 2
A: CT scan showed that there was a mass on left upper lobe (September 10, 2015); B: follow up CT scan showed that the mass on left upper lobe reduction; C and D: CT scan showed that there was lymph nodes metastasis in mediastinum (3A prevascular and right pulmonary ligament). Pleural effusion occurred at the thoracic cavity. Left upper lobe residual mass was steady; E and F: Radiotherapy (IMRT 2 Gy/fraction total DT: 40 Gy/20 fraction); G and H: One months later, CT scan showed that metastases lymph notes of mediastinum (3A prevascular and right pulmonary ligament) reduced partially, therapeutic evaluation partial remission (PR) and the mass of Left upper lobe residual reduced partially as well and pleural effusion reduced; I: The common side effects of apatinib was hand-foot syndrome. CT = computed tomography.

References

    1. O’Rourke N, Roque IFM, Farre Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;Cd002140. - PubMed
    1. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617–25. - PMC - PubMed
    1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31. - PubMed
    1. Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014;2:123. - PMC - PubMed
    1. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007;13(18 Pt 2):5544s–8s. - PubMed

Publication types

LinkOut - more resources